ABCL Q2 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+133.3% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$50M-290.2% margin

Net Income

-$35M-203.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+303.4%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$46M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$395M

Stockholders' Equity

$1.0B

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$7M	+133.3%
Gross Profit	$17M	$7M	+133.3%
Operating Income	-$50M	-$93M	+46.9%
Net Income	-$35M	-$37M	+6.0%

Revenue Segments

License

$10M61%

Research Fees

$7M39%